T
Theresa Wagner
Researcher at University of Vienna
Publications - 6
Citations - 1662
Theresa Wagner is an academic researcher from University of Vienna. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 6, co-authored 6 publications receiving 1588 citations. Previous affiliations of Theresa Wagner include Peter MacCallum Cancer Centre.
Papers
More filters
Journal ArticleDOI
Effect of Short-Term Hormone Replacement Therapy on Breast Cancer Risk Reduction After Bilateral Prophylactic Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group
Timothy R. Rebbeck,Tara M. Friebel,Theresa Wagner,Henry T. Lynch,Judy Garber,Mary B. Daly,Claudine Isaacs,Olufunmilayo I. Olopade,Susan L. Neuhausen,Laura van 't Veer,Rosalind A. Eeles,D. Gareth Evans,Gail E. Tomlinson,Ellen T. Matloff,Steven A. Narod,Andrea Eisen,Susan M. Domchek,Katrina Armstrong,Barbara L. Weber +18 more
TL;DR: Short-term HRT use does not negate the protective effect of BPO on subsequent breast cancer risk in BRCA1/2 mutation carriers, and HRT of any type after BPO did not significantly alter the reduction in breast cancerrisk associated with BPO.
Journal ArticleDOI
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
Steven A. Narod,Marie-Pierre Dubé,Jan Klijn,Jan Lubinski,Henry T. Lynch,Parviz Ghadirian,Daine Provencher,Ketil Heimdal,Pål Møller,Mark E. Robson,Kenneth Offit,Claudine Isaacs,Barbara L. Weber,Eitan Friedman,Ruth Gershoni-Baruch,Gad Rennert,Barbara Pasini,Theresa Wagner,Mary B. Daly,Judy Garber,Susan L. Neuhausen,Peter Ainsworth,Håkan Olsson,Gareth Evans,Michael P. Osborne,Fergus J. Couch,William D. Foulkes,Ellen Warner,Charmaine Kim-Sing,Olufunmilayo I. Olopade,Nadine Tung,Howard M. Saal,Jeffrey N. Weitzel,Sofia D. Merajver,Marion Gauthier-Villars,Helena Jernström,Ping Sun,Jean Sébastien Brunet +37 more
TL;DR: Among BRCA1 mutation carriers, women who first used oral contraceptives before 1975, who used them before age 30, or who use them for 5 or more years may have an increased risk of early-onset breast cancer.
Journal ArticleDOI
Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study
Susan M. Domchek,Tara M. Friebel,Susan L. Neuhausen,Theresa Wagner,Gareth Evans,Claudine Isaacs,Judy Garber,Mary B. Daly,Rosalind A. Eeles,Ellen T. Matloff,Gail E. Tomlinson,Laura J. van't Veer,Henry T. Lynch,Olufunmilayo I. Olopade,Barbara L. Weber,Barbara L. Weber,Timothy R. Rebbeck +16 more
TL;DR: If confirmed, the finding that BPSO improves overall survival and cancer-specific survival in women with BRCA mutations will complement the existing knowledge of cancer-risk reduction associated with B PSO and give information to women who are considering genetic testing.
Journal ArticleDOI
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
Antonis Antoniou,Antonis Antoniou,Amanda B. Spurdle,Amanda B. Spurdle,Olga M. Sinilnikova,Olga M. Sinilnikova,Sue Healey,Sue Healey,Karen A. Pooley,Karen A. Pooley,Rita K. Schmutzler,Rita K. Schmutzler,Beatrix Versmold,Beatrix Versmold,Christoph Engel,Christoph Engel,Alfons Meindl,Alfons Meindl,Norbert Arnold,Norbert Arnold,W. Hofmann,W. Hofmann,Christian Sutter,Christian Sutter,Dieter Niederacher,Dieter Niederacher,Helmut Deissler,Helmut Deissler,Trinidad Caldés,Trinidad Caldés,Kati Kämpjärvi,Kati Kämpjärvi,Heli Nevanlinna,Heli Nevanlinna,Jacques Simard,Jacques Simard,Jonathan Beesley,Jonathan Beesley,Xiaoqing Chen,Xiaoqing Chen,Susan L. Neuhausen,Susan L. Neuhausen,Timothy R. Rebbeck,Timothy R. Rebbeck,Theresa Wagner,Theresa Wagner,Henry T. Lynch,Claudine Isaacs,Claudine Isaacs,Jeffrey N. Weitzel,Jeffrey N. Weitzel,Patricia A. Ganz,Patricia A. Ganz,Mary B. Daly,Mary B. Daly,Gail E. Tomlinson,Gail E. Tomlinson,Olufunmilayo I. Olopade,Joanne L. Blum,Joanne L. Blum,Fergus J. Couch,Paolo Peterlongo,Siranoush Manoukian,M. Barile,Paolo Radice,Csilla Szabo,Lutecia Pereira,Lutecia Pereira,Mark H. Greene,Mark H. Greene,Gad Rennert,Gad Rennert,Flavio Lejbkowicz,Flavio Lejbkowicz,Ofra Barnett-Griness,Ofra Barnett-Griness,Irene L. Andrulis,Irene L. Andrulis,Irene L. Andrulis,Hilmi Ozcelik,Hilmi Ozcelik,Anne-Marie Gerdes,Anne-Marie Gerdes,Maria A. Caligo,Maria A. Caligo,Yael Laitman,Bella Kaufman,Bella Kaufman,Roni Milgrom,Eitan Friedman,Eitan Friedman,Susan M. Domchek,Katherine L. Nathanson,Ana Osorio,Gemma Llort,Roger L. Milne,Javier Benítez,Javier Benítez,Ute Hamann,Frans B L Hogervorst,Frans B L Hogervorst,Peggy Manders,Marjolijn J L Ligtenberg,Ans M.W. van den Ouweland,Susan Peock,Susan Peock,M. Cook,M. Cook,Radka Platte,Radka Platte,D. Gareth Evans,Rosalind A. Eeles,Gabriella Pichert,Carol Chu,Diana Eccles,Rosemarie Davidson,Fiona Douglas,Andrew K. Godwin,Andrew K. Godwin,Laure Barjhoux,Laure Barjhoux,Sylvie Mazoyer,Sylvie Mazoyer,Hagay Sobol,Violaine Bourdon,François Eisinger,Agnès Chompret,Agnès Chompret,Corinne Capoulade,Brigitte Bressac-de Paillerets,Gilbert M. Lenoir,Marion Gauthier-Villars,Claude Houdayer,Dominique Stoppa-Lyonnet,Georgia Chenevix-Trench,Georgia Chenevix-Trench,Douglas F. Easton,Douglas F. Easton +137 more
TL;DR: Differences in the effects of the FGFR2 and MAP3K1 SNPs between BRCA1 and BRCa2 carriers point to differences in the biology of BRC a1 and bRCA2 breast cancer tumors and confirm the distinct nature of breast cancer in BRC A1 mutation carriers.
Journal ArticleDOI
RAD51 135G→C Modifies Breast Cancer Risk among BRCA2 Mutation Carriers: Results from a Combined Analysis of 19 Studies
Antonis C. Antoniou,Olga M. Sinilnikova,Jacques Simard,Mélanie Léoné,Martine Dumont,Susan L. Neuhausen,Jeffery P. Struewing,Dominique Stoppa-Lyonnet,Laure Barjhoux,David J. Hughes,Isabelle Coupier,Muriel Belotti,Christine Lasset,Valérie Bonadona,Yves-Jean Bignon,Timothy R. Rebbeck,Theresa Wagner,Henry T. Lynch,Susan M. Domchek,Katherine L. Nathanson,Judy Garber,Jeffrey N. Weitzel,Steven A. Narod,Gail E. Tomlinson,Olufunmilayo I. Olopade,Andrew K. Godwin,Claudine Isaacs,Anna Jakubowska,Jan Lubinski,Jacek Gronwald,Bohdan Górski,Tomasz Byrski,Tomasz Huzarski,Susan Peock,Margaret Cook,Caroline Baynes,Alexandra Murray,Mark T. Rogers,Peter A. Daly,Huw Dorkins,Rita K. Schmutzler,Beatrix Versmold,Christoph Engel,Alfons Meindl,Norbert Arnold,Dieter Niederacher,Helmut Deissler,Amanda B. Spurdle,Xiaoqing Chen,Nicola Waddell,Nicole Cloonan,Tomas Kirchhoff,Kenneth Offit,Eitan Friedman,Bella Kaufmann,Yael Laitman,Gilli Galore,Gad Rennert,Flavio Lejbkowicz,Leon Raskin,Irene L. Andrulis,Eduard Ilyushik,Hilmi Ozcelik,Peter Devilee,Maaike P.G. Vreeswijk,Mark H. Greene,Sheila A. Prindiville,Ana Osorio,Javier Benitez,Michal Zikan,Csilla Szabo,Outi Kilpivaara,Heli Nevanlinna,Ute Hamann,Francine Durocher,Adalgeir Arason,Fergus J. Couch,Douglas F. Easton,Georgia Chenevix-Trench +78 more
TL;DR: RAD51 is the first gene to be reliably identified as a modifier of risk among BRCA1/2 mutation carriers and it is determined that the 135G-->C variant affects RAD51 splicing within the 5' UTR.